[Comparison of the effectiveness of budesonide and prednisone in the maintenance treatment of pulmonary sarcoidosis].
The aim of this investigation was to compare inhaled budesonide vs oral prednisone in the maintenance phase treatment of pulmonary sarcoidosis. Double-blind controlled study was performed in 40 patients with stage II or III pulmonary sarcoidosis. After initial systemic 6 weeks treatment with prednisone (40 reduced to 20 mg daily) patients were allocated either to systematically (P) or topically (B) treated group. P patients continued with 10 mg prednisone daily, B patients were given inhaled budesonide 1.6 mg daily. The progress of treatment was assessed by serial radiography, spirometry, serum ACE activity and plasma cortisol levels. All patients completed the 12 months treatment. Using a numerical score to assess changes on the chest radiograms P patients improved by 1.7 +/- 0.66 points; B patients improved by 1.15 +/- 0.81 points. Spirometric changes were insignificant. Serum ACE fell from 107 +/- 51 U/L in the P group and 92 +/- 40 U/L in the B group to 46 +/- 11 U/L and 38 +/- 21 U/L respectively during the initial phase of treatment. In the maintenance phase ACE levels remained lower than initial ones in both groups. Morning cortisol plasma levels studied in 10 patients (5 in each group) decreased significantly during the initial phase. Thereafter cortisol levels remained low in the P patients returning to the lower limit of normal values in the B patients. We conclude that inhaled budesonide may be a safe and effective alternative to oral steroids in the maintenance treatment of pulmonary sarcoidosis especially in the early, stage II, disease.
Zych
D
D
Kliniki Chorób Płuc, Instytutu Gruźlicy i Chorób Płuc.
Pawlicka
L
L
Zieliński
J
J
D000280:Administration, Inhalation; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D019819:Budesonide; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011241:Prednisone / Q000008:administration & dosage*; D011282:Pregnenediones / Q000008:administration & dosage*; D012119:Respiration / Q000187:drug effects* / Q000502:physiology; D012507:Sarcoidosis / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
D001993:Bronchodilator Agents; D010919:Placebos; D011282:Pregnenediones; D019819:Budesonide; D011241:Prednisone
Porównanie skuteczności budezonidu i prednizonu w podtrzymujacym okresie leczenia sarkoidozy płuc.